Clinical Report: Prescribing for Dry Eye Disease
Overview
Recent advancements in the treatment of dry eye disease (DED) highlight a variety of interventions tailored to specific etiologies. The TFOS DEWS III report provides a structured algorithm for prescribing based on the underlying causes of DED, emphasizing a targeted approach to therapy.
Background
Dry eye disease is a multifactorial condition that significantly impacts patients' quality of life. Understanding the various pathogenic drivers of DED is crucial for effective management and treatment. The recent TFOS DEWS III report offers updated guidelines that can aid healthcare professionals in making informed prescribing decisions.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
- The TFOS DEWS III report categorizes DED drivers into three main groups: tear film deficiencies, eyelid abnormalities, and ocular surface abnormalities.
- Common therapies for DED include artificial tears, lid hygiene, and nutraceuticals, with a focus on addressing the main causes first.
- Meibomian gland dysfunction (MGD) is a primary cause of evaporative DED, requiring targeted therapies such as vitamin D3 and in-office tear stimulation devices.
- Intense pulsed light (IPL) therapy is recommended for ocular rosacea with lid telangiectasia, while oral antibiotics may be prescribed as an alternative.
- Patients with inadequate lid closure may benefit from moisture chamber goggles or ointments, especially if they use CPAP machines.
Clinical Implications
Clinicians should adopt a stepwise, etiology-based approach when prescribing treatments for DED. It is essential to assess the primary drivers of the disease and tailor interventions accordingly, potentially combining therapies for optimal patient outcomes.
Conclusion
The evolving landscape of DED treatment necessitates a comprehensive understanding of its multifactorial nature. The TFOS DEWS III report serves as a valuable resource for clinicians to enhance their prescribing practices.
References
- Tear Film and Ocular Surface Society, TFOS DEWS III Report, 2025 -- Management and Therapy Report
- Frontiers, 2024 -- Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials
- PubMed, 2024 -- Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction-A systematic review and meta-analysis
- Contact Lens Spectrum — Dry Eye Dx and Tx
- Contact Lens Spectrum — Dry Eye Dx and Tx
- Ophthalmology Management — Treating Dry Eye: An Opportunity to Build Patient Loyalty
- Ophthalmology Management — The Profound Impact of Dry Eye Disease on Patients' Lives
- Dry Eye Dx and Tx, Contact Lens Spectrum, July 2013
- When Dry Eye Isn't Just Dry Eye, Part 2, Contact Lens Spectrum, November 2013
- Treating Dry Eye: An Opportunity to Build Patient Loyalty, Ophthalmology Management, April 2007
- https://utstyrsavdelingen.no/wp-content/uploads/2024/02/TFOS-DEWS-III-Management-and-Therapy-Report.pdf
- Frontiers | Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials
- Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction-A systematic review and meta-analysis - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.